

A
Myelination (MBP % of control)
200
150
100
50
0
*
+73%
Ctl
MIX7 – Dose1
B
Myelination (MBP % of control)
180
160
140
120
100
80
60
40
20
0
ns
Tg
SRB - 500µM
C
180
160
140
120
100
80
60
40
20
0
ns
Tg
BCL 5µM
D
180
160
140
120
100
80
60
40
20
0
ns
Tg
NTX 5µM

Figure 1



A
Myelination (MBP % of control)
200
180
160
140
120
100
80
60
40
20
0
*
+75%
Ctl
MIX7 – Dose6
B
Myelination (MBP % of control)
180
160
140
120
100
80
60
40
20
0
ns
Ctl
SRB - 160nM
C
180
160
140
120
100
80
60
40
20
0
Ctl
BCL 1,6nM
D
180
160
140
120
100
80
60
40
20
0
ns
Ctl
NTX 1,6nM

Figure 2



A
Myelination (MBP % of control)
200
150
100
50
0
+35%
+75%
+64%
+53%
+48%
+45%
+73%
Ctl
Dose 7
Dose 6
Dose 5
Dose 4
Dose 3
Dose 2
Dose 1
B
Myelination (MBP % of control)
250
200
150
100
50
0
P=0.059
Ctl
Dose 7
Dose 6
Dose 5
Dose 4
Dose 3
Dose 2
Dose 1

Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9

	Groups of performances in inclined plane test			
	Poor score	Intermediate score	Good score	*p-value (vs TG placebo)*
WT placebo	11%	21%	68%	*0,0003*
TG placebo	**60%**	**35%**	**5%**	-
Mix7-dose2	**29%**	**41%**	**29%**	***0,0152***
Mix7-dose3	**11%**	**56%**	**33%**	***0,0020***

Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16



A
Surface bearing ratio (ipsi/contra)
1.0
0.8
0.6
**
Sham
Crush
B
Surface bearing ratio (ipsi/contra)
1.0
0.8
0.6
*
Crush
Crush + mix7
C
Surface bearing ratio (ipsi/contra)
1.0
0.8
0.6
ns
Crush
Crush + BCL
D
Surface bearing ratio (ipsi/contra)
1.0
0.8
0.6
ns
Crush
Crush + NTX
E
Surface bearing ratio (ipsi/contra)
1.0
0.8
0.6
ns
Crush
Crush + SRB

Figure 17